Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 27

1.

Radio-immunotherapy and chemo-immunotherapy as a novel treatment paradigm in malignant pleural mesothelioma.

Wu L, de Perrot M.

Transl Lung Cancer Res. 2017 Jun;6(3):325-334. doi: 10.21037/tlcr.2017.06.03. Review.

2.

Novel systemic therapy against malignant pleural mesothelioma.

Mancuso MR, Neal JW.

Transl Lung Cancer Res. 2017 Jun;6(3):295-314. doi: 10.21037/tlcr.2017.06.01. Review.

3.

Modern management of malignant pleural mesothelioma.

Patel SC, Dowell JE.

Lung Cancer (Auckl). 2016 May 3;7:63-72. doi: 10.2147/LCTT.S83338. eCollection 2016. Review.

4.

Clinical role of a new prognostic score using platelet-to-lymphocyte ratio in patients with malignant pleural mesothelioma undergoing extrapleural pneumonectomy.

Tagawa T, Anraku M, Morodomi Y, Takenaka T, Okamoto T, Takenoyama M, Ichinose Y, Maehara Y, Cho BC, Feld R, Tsao MS, Leighl N, Bezjak A, Keshavjee S, de Perrot M.

J Thorac Dis. 2015 Nov;7(11):1898-906. doi: 10.3978/j.issn.2072-1439.2015.11.15. Erratum in: J Thorac Dis. 2016 Jan;8(1):E161.

5.

Trimodality strategy for treating malignant pleural mesothelioma: results of a feasibility study of induction pemetrexed plus cisplatin followed by extrapleural pneumonectomy and postoperative hemithoracic radiation (Japan Mesothelioma Interest Group 0601 Trial).

Hasegawa S, Okada M, Tanaka F, Yamanaka T, Soejima T, Kamikonya N, Tsujimura T, Fukuoka K, Yokoi K, Nakano T.

Int J Clin Oncol. 2016 Jun;21(3):523-30. doi: 10.1007/s10147-015-0925-1. Epub 2015 Nov 17.

6.

The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: A comprehensive analysis reveals prognostic immune markers.

Ujiie H, Kadota K, Nitadori JI, Aerts JG, Woo KM, Sima CS, Travis WD, Jones DR, Krug LM, Adusumilli PS.

Oncoimmunology. 2015 Mar 19;4(6):e1009285. eCollection 2015 Jun.

7.

Surgical cytoreduction restores the antitumor efficacy of a Listeria monocytogenes vaccine in malignant pleural mesothelioma.

Kennedy GT, Judy BF, Bhojnagarwala P, Moon EK, Fridlender ZG, Albelda SM, Singhal S.

Immunol Lett. 2015 Jul;166(1):28-35. doi: 10.1016/j.imlet.2015.05.009. Epub 2015 May 18.

8.

Clinical experience of volumetric modulated arc therapy for malignant pleural mesothelioma after extrapleural pneumonectomy.

Kimura T, Doi Y, Nakashima T, Imano N, Katsuta T, Takahashi S, Kenjo M, Ozawa S, Murakami Y, Nagata Y.

J Radiat Res. 2015 Mar;56(2):315-24. doi: 10.1093/jrr/rru102. Epub 2015 Jan 18.

9.

Current issues in malignant pleural mesothelioma evaluation and management.

Ai J, Stevenson JP.

Oncologist. 2014 Sep;19(9):975-84. doi: 10.1634/theoncologist.2014-0122. Epub 2014 Jul 24.

10.

Malignant pleural mesothelioma: a single-center experience in Turkey.

Sezer A, Sümbül AT, Abalı H, Mertsoylu H, Ozyılkan O.

Med Sci Monit. 2014 May 20;20:825-32. doi: 10.12659/MSM.890020.

11.

Guidelines for the diagnosis and treatment of malignant pleural mesothelioma.

van Zandwijk N, Clarke C, Henderson D, Musk AW, Fong K, Nowak A, Loneragan R, McCaughan B, Boyer M, Feigen M, Currow D, Schofield P, Nick Pavlakis BI, McLean J, Marshall H, Leong S, Keena V, Penman A.

J Thorac Dis. 2013 Dec;5(6):E254-307. doi: 10.3978/j.issn.2072-1439.2013.11.28. Review. No abstract available.

12.

Identification of a seven glycopeptide signature for malignant pleural mesothelioma in human serum by selected reaction monitoring.

Cerciello F, Choi M, Nicastri A, Bausch-Fluck D, Ziegler A, Vitek O, Felley-Bosco E, Stahel R, Aebersold R, Wollscheid B.

Clin Proteomics. 2013 Nov 8;10(1):16. doi: 10.1186/1559-0275-10-16.

13.
14.

Radical surgery for malignant pleural mesothelioma: have we identified the appropriate selection tools?

van Zandwijk N, Reid G, Linton A, Kao S.

Ann Cardiothorac Surg. 2012 Nov;1(4):481-6. doi: 10.3978/j.issn.2225-319X.2012.10.01. No abstract available.

15.

Mesothelin-targeted immunotherapies for malignant pleural mesothelioma.

Villena-Vargas J, Adusumilli PS.

Ann Cardiothorac Surg. 2012 Nov;1(4):466-71. doi: 10.3978/j.issn.2225-319X.2012.10.03. No abstract available.

16.

Novel radiation therapy approaches in malignant pleural mesothelioma.

Rimner A, Rosenzweig KE.

Ann Cardiothorac Surg. 2012 Nov;1(4):457-61. doi: 10.3978/j.issn.2225-319X.2012.10.07. No abstract available.

17.

A seven-year disease-free survivor of malignant pleural mesothelioma treated with hyperthermia and chemotherapy: a case report.

Okonogi N, Ebara T, Ishikawa H, Yoshida D, Ueno M, Maeno T, Suga T, Nakano T.

J Med Case Rep. 2012 Dec 28;6:427. doi: 10.1186/1752-1947-6-427.

18.

Pegylated liposomal doxorubicin in malignant pleural mesothelioma: a possible guardian for long-term survival.

Zarogoulidis P, Mavroudi M, Porpodis K, Domvri K, Sakkas A, Machairiotis N, Stylianaki A, Tsiotsios A, Courcoutsakis N, Zarogoulidis K.

Onco Targets Ther. 2012;5:231-6. doi: 10.2147/OTT.S36915. Epub 2012 Sep 27.

19.

Investigational approaches for mesothelioma.

Surmont VF, van Thiel ER, Vermaelen K, van Meerbeeck JP.

Front Oncol. 2011 Aug 22;1:22. doi: 10.3389/fonc.2011.00022. eCollection 2011.

20.

Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma.

Bograd AJ, Suzuki K, Vertes E, Colovos C, Morales EA, Sadelain M, Adusumilli PS.

Cancer Immunol Immunother. 2011 Nov;60(11):1509-27. doi: 10.1007/s00262-011-1103-6. Epub 2011 Sep 13. Review.

Supplemental Content

Support Center